Summary of immunochromatographic strip studies (n=3)
| First author, year, reference | Country | Study population | Symptomatic (%) | Sex | Sample size (n) | POC test brand name | Gold standard | Gonorrhoea prevalence (%) | Specimen type | Sensitivity % (95% CI) | Specificity % (95% CI) | PPV % (95% CI) | NPV % (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alary, 200613 | Benin | Sex worker | 5.4 | F | 1084 | GC Check | NAAT Amplicor CT/NG (Roche, location not specified) | 4.6 | Cervical swab – Vaginal swab | 70 (55 to 82) – 54 (37 to 71) | 97 (96 to 98) – 98 (9& to 99) | 55 (50 to 76)* – 61 (42 to 76) | 98.7 (98 to 99)* – 97.7 (96 to 98)* |
| Benzaken, 20063 | Brazil | STI clinic attendees | High risk† | F | 326 | Biostar | Culture Modified Thayer–Martin | 15.0 | Cervical Swab | 60 (46 to 74) | 89 (86 to 94) | 56 (42 to 69) | 92.6 (89.5 to 95.7) |
| Suzuki, 200426 | Japan | Urology department | 100 | M | 58 | NOW Gonorrhoea Test | Culture Thayer–Martin | 58.6 | Urine | 94 (80 to 99)* | 96 (79 to 100)* | 97* (84 to 100)* | 92 (75 to 98) |
*Calculated by author.
†Referred by sexual partner or symptomatic.
GUM, genitourinary medicine; NAAT, nucleic acid amplification test; NPV, negative predictive value; POC, point-of-care; PPV, positive predictive value; STI, sexually transmitted infection.